Overview
Paul Radensky observed that, while an effort to regulate lab-developed tests is an area that FDA staff would “like to move forward” because they have been interested in it for more than a decade, any movement’s “what, how and when will definitely depend on who is in the leadership” at the FDA under the Trump Administration.